When C57Bl/6 mice (10 mice/group) bearing B16-F10 tumors (~5mm diameter) were exposed to a daily dose of 100 mg/kg palbociclib, 50 mg/kg of the CDK2 inhibitor, PF-07104091, with control chow or SX-682 chow, the toxicity of palbociclib plus PF-07104091 or the triple therapy was acceptable and anti-tumor efficacy of the triple combination with SX-682 was increased relative CDK4/6 plus CDK2 inhibition or SX-682 alone (Figures 6A, B), resulting in a failure of tumors to grow. The gene discussed is CDK4; the disease is neoplasm.